Co-Authors
This is a "connection" page, showing publications co-authored by STEVEN G WAGUESPACK and ERIC JONASCH.
Connection Strength
0.427
-
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018 10; 19(10):1351-1359.
Score: 0.164
-
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec; 22(12):2661-2666.
Score: 0.102
-
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb; 94(2):386-91.
Score: 0.083
-
Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 10 01; 129(19):2927-2940.
Score: 0.057
-
A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. Cancer Invest. 2008 Jul; 26(6):642-6.
Score: 0.020